Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
30 participants
Study Classification
INTERVENTIONAL
Study Start Date
2014-10-31
Study Completion Date
2018-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
People with multiple sclerosis (MS) have nerve loss even without acute inflammatory relapses, as obvious in the progressive phase of disease. Drugs that may prevent nerve loss work better in earlier stages when it is difficult to measure progressive disability. But it is now possible to measure the nerve loss as neurofilament light (NFL) in the cerebrospinal fluid (CSF). This is a trial of a neuroprotective drug, oxcarbazepine, which showed benefit in an animal model of multiple sclerosis. The investigators will use an innovative outcome, a reduction in the content of NFL in the CSF, as well as the usual clinical disability and imaging methods, to measure the success of the oxcarbazepine as a neuroprotective agent in MS. The use of NFL, a surrogate marker of neurodegeneration, allows a blinded and accurate outcome.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis
NCT06495593
Multiple Sclerosis, Relapsing-Remitting
RECRUITING
PHASE4
Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation
NCT04230174
Multiple Sclerosis
COMPLETED
PHASE4
Stem Cells in Rapidly Evolving Active Multiple Sclerosis
NCT01606215
Multiple Sclerosis
COMPLETED
PHASE1/PHASE2
Simvastatin in Secondary Progressive Multiple Sclerosis
NCT03896217
Secondary Progressive Multiple Sclerosis
COMPLETED
PHASE2
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
NCT07207148
Multiple Sclerosis
NOT_YET_RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients who have been identified as potentially eligible for this trial and referred to us will be invited to take part in the study and provided with information given as a patient information sheet. This includes patients with clinical definite MS who are on any DMDs, have not had a MS relapses for at least 6 months and feel (subjective) or are observed (objective) to have progressing disability.
For screening patients will sign the informed consent form after discussion and make sure they fulfil inclusion and exclusion criteria, they will have a neurological and a brief suicidality assessment and will have safety blood and urine tests. Patients will have a lumbar puncture to measure NFL in CSF. If it is above the threshold, showing that there is ongoing damage to the myelin, we will invite them to continue in the trial.
Patients will have a baseline brain and spinal cord MRI and OCT, clinical/neurological examination and will have a repeat lumbar puncture and collection of blood, urine and saliva. Patients will be blindly randomised to oxcarbazepine vs placebo and given the bottles of medication with each participant's individualised label.
At two and four weeks after the baseline visit, patients will have a phone visit when investigators will collect details of new symptoms, new medication and generally advise participants. The tablets should have been increases to two tablets in the morning and two tablets in the evening.
Patients will be seen by the study team at 13 weeks after initiation of the drug and again at 25 and 37 weeks when they will have an OCT, lumbar puncture, collection of blood, urine and saliva after general, visual, neurological and cognitive assessments/questionnaires.
The final visit will be at week 48, when a final lumbar puncture, preceded by clinical measures including general, visual, neurological and cognitive assessments/questionnaires, MRI , OCT and blood, urine \& saliva collection.
The measurement of NFL will be repeated from the CSF samples on the same at the end of the study to determine whether patients with MS who were on oxcarbazepine had a reduction in the levels of CSF NFL.
For screening patients will sign the informed consent form after discussion and make sure they fulfil inclusion and exclusion criteria, they will have a neurological and a brief suicidality assessment and will have safety blood and urine tests. Patients will have a lumbar puncture to measure NFL in CSF. If it is above the threshold, showing that there is ongoing damage to the myelin, we will invite them to continue in the trial.
Patients will have a baseline brain and spinal cord MRI and OCT, clinical/neurological examination and will have a repeat lumbar puncture and collection of blood, urine and saliva. Patients will be blindly randomised to oxcarbazepine vs placebo and given the bottles of medication with each participant's individualised label.
At two and four weeks after the baseline visit, patients will have a phone visit when investigators will collect details of new symptoms, new medication and generally advise participants. The tablets should have been increases to two tablets in the morning and two tablets in the evening.
Patients will be seen by the study team at 13 weeks after initiation of the drug and again at 25 and 37 weeks when they will have an OCT, lumbar puncture, collection of blood, urine and saliva after general, visual, neurological and cognitive assessments/questionnaires.
The final visit will be at week 48, when a final lumbar puncture, preceded by clinical measures including general, visual, neurological and cognitive assessments/questionnaires, MRI , OCT and blood, urine \& saliva collection.
The measurement of NFL will be repeated from the CSF samples on the same at the end of the study to determine whether patients with MS who were on oxcarbazepine had a reduction in the levels of CSF NFL.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Multiple Sclerosis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
OxCarbazepine Treatment
Treated for 48 weeks with OxCarbazepine 150mg twice a day alongside current DMDs.
Group Type
EXPERIMENTAL
Oxcarbazepine
Intervention Type
DRUG
Oxcarbazepine 150mg tablet, over encapsulated and back-filled with Microcrystalline Cellulose/Magnesium Stearate 1%.
OxCarbazepine Placebo
Treated for 48 weeks with matched placebo 1 tablet twice a day alongside current DMDs
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
DRUG
Placebo in a matched capsule containing Microcrystalline Cellulose/Magnesium Stearate 1%.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oxcarbazepine
Oxcarbazepine 150mg tablet, over encapsulated and back-filled with Microcrystalline Cellulose/Magnesium Stearate 1%.
Intervention Type
DRUG
Placebo
Placebo in a matched capsule containing Microcrystalline Cellulose/Magnesium Stearate 1%.
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Trileptal
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A diagnosis of definite multiple sclerosis
* Treatment with DMDs for at least 6 months prior to baseline visit\*
* CSF NFL level ≥ 0.380ng/mL
* EDSS score between 3.5 and 6.0
* No history of relapses in the 6 months prior to the baseline visit
* A history of slow progression of disability, objective or subjective, over a period of at least 6 months prior to baseline
* Age 18-60 years
* \[Temporary interruption is permitted at the discretion of the investigator for a period of up to 8 weeks to prevent inflammatory MS reactivation. The cases where this could happen include for example switching DMDs that require a washout period as per clinical practice. When there are safety concerns, as in Lymphopenia or other side effects induced by the DMD, the interruption period can exceed 8 weeks as per clinical need. If reactivation of MS occurs with a relapse the investigator will assess if this meets withdrawal criteria 6.\]
* Treatment with DMDs for at least 6 months prior to baseline visit\*
* CSF NFL level ≥ 0.380ng/mL
* EDSS score between 3.5 and 6.0
* No history of relapses in the 6 months prior to the baseline visit
* A history of slow progression of disability, objective or subjective, over a period of at least 6 months prior to baseline
* Age 18-60 years
* \[Temporary interruption is permitted at the discretion of the investigator for a period of up to 8 weeks to prevent inflammatory MS reactivation. The cases where this could happen include for example switching DMDs that require a washout period as per clinical practice. When there are safety concerns, as in Lymphopenia or other side effects induced by the DMD, the interruption period can exceed 8 weeks as per clinical need. If reactivation of MS occurs with a relapse the investigator will assess if this meets withdrawal criteria 6.\]
Exclusion Criteria
* Pregnant or breastfeeding or unwilling to use adequate contraception.\*
* Participants with a diagnosis of primary progressive PP MS or primary relapsing PR MS.
* A clinical relapse or pulsed intravenous or oral steroids in the 6 months preceding the baseline assessment.
* Participants presenting with medical disorder deemed severe or unstable by the CI such as poorly controlled diabetes or arterial hypertension, severe cardiac insufficiency, unstable ischemic heart disease, abnormal liver function tests (\>2.5 times ULN) and abnormal complete blood count (in particular leukopenia, as defined by a lymphocyte count \<500, neutrophil count \<1.5 or platelet count \<100, or thrombocytopenia \<1.5 LLN), or any medical condition which, in the opinion of the investigator, would pose additional risk to the participant.
* Infection with hepatitis B or hepatitis C or human immunodeficiency virus.
* Exposure to any other investigational drug within 30 days of enrolment in the study.
* Judged clinically to have a suicidal risk in the opinion of the investigator based upon a clinical interview and the Columbia Suicide-Severity Rating Scale (CSSRS).
* Prior history of malignancy unless an exception is granted by the Investigator.
* History of uncontrolled drug or alcohol abuse within 6 months prior to screening.
* Past untoward reactions to OxCbz or Cbz
* Participants receiving OxCbz or Cbz in the previous 12 weeks from baseline
* \[Adequate methods of contraception are non hormonal methods such as barrier methods, intrauterine devices, surgical sterilisation (undergone by the participant or their partner). Female participants using hormonal only forms of contraception will be required to use an additional barrier method. True abstinence can be considered an acceptable method of contraception when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial, and withdrawal are not acceptable methods of contraception. Non sexually active participants or those in same sex relationships will not be required to commence contraception.\]
* Participants with a diagnosis of primary progressive PP MS or primary relapsing PR MS.
* A clinical relapse or pulsed intravenous or oral steroids in the 6 months preceding the baseline assessment.
* Participants presenting with medical disorder deemed severe or unstable by the CI such as poorly controlled diabetes or arterial hypertension, severe cardiac insufficiency, unstable ischemic heart disease, abnormal liver function tests (\>2.5 times ULN) and abnormal complete blood count (in particular leukopenia, as defined by a lymphocyte count \<500, neutrophil count \<1.5 or platelet count \<100, or thrombocytopenia \<1.5 LLN), or any medical condition which, in the opinion of the investigator, would pose additional risk to the participant.
* Infection with hepatitis B or hepatitis C or human immunodeficiency virus.
* Exposure to any other investigational drug within 30 days of enrolment in the study.
* Judged clinically to have a suicidal risk in the opinion of the investigator based upon a clinical interview and the Columbia Suicide-Severity Rating Scale (CSSRS).
* Prior history of malignancy unless an exception is granted by the Investigator.
* History of uncontrolled drug or alcohol abuse within 6 months prior to screening.
* Past untoward reactions to OxCbz or Cbz
* Participants receiving OxCbz or Cbz in the previous 12 weeks from baseline
* \[Adequate methods of contraception are non hormonal methods such as barrier methods, intrauterine devices, surgical sterilisation (undergone by the participant or their partner). Female participants using hormonal only forms of contraception will be required to use an additional barrier method. True abstinence can be considered an acceptable method of contraception when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of a trial, and withdrawal are not acceptable methods of contraception. Non sexually active participants or those in same sex relationships will not be required to commence contraception.\]
Minimum Eligible Age
18 Years
Maximum Eligible Age
60 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Multiple Sclerosis Society
OTHER
Sponsor Role
collaborator
Novartis Pharmaceuticals
INDUSTRY
Sponsor Role
collaborator
Barts & The London NHS Trust
OTHER
Sponsor Role
collaborator
University College, London
OTHER
Sponsor Role
collaborator
Royal Free Hospital NHS Foundation Trust
OTHER
Sponsor Role
collaborator
Mid and South Essex NHS Foundation Trust
OTHER
Sponsor Role
collaborator
St George's Healthcare NHS Trust
OTHER
Sponsor Role
collaborator
Barnet and Chase Farm Hospitals NHS Trust
OTHER
Sponsor Role
collaborator
Queen Mary University of London
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gavin Givannoni
Role: PRINCIPAL_INVESTIGATOR
Queen Mary University of London
Monica Calado Marta
Role: PRINCIPAL_INVESTIGATOR
Barts & The London NHS Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Barts Health NHS Trust
London, , United Kingdom
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United Kingdom
References
Explore related publications, articles, or registry entries linked to this study.
Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998 Jan 29;338(5):278-85. doi: 10.1056/NEJM199801293380502.
Reference Type
BACKGROUND
Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J, Edan G. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010 Jul;133(Pt 7):1900-13. doi: 10.1093/brain/awq076. Epub 2010 Apr 27.
Reference Type
BACKGROUND
Petzold A, de Boer JF, Schippling S, Vermersch P, Kardon R, Green A, Calabresi PA, Polman C. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 2010 Sep;9(9):921-32. doi: 10.1016/S1474-4422(10)70168-X.
Reference Type
BACKGROUND
Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, Seaman S, Miller DH, Hale G, Waldmann H, Compston DA. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006 Jan;253(1):98-108. doi: 10.1007/s00415-005-0934-5. Epub 2005 Jul 27.
Reference Type
BACKGROUND
Franklin RJ, Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci. 2008 Nov;9(11):839-55. doi: 10.1038/nrn2480.
Reference Type
BACKGROUND
Stys PK. General mechanisms of axonal damage and its prevention. J Neurol Sci. 2005 Jun 15;233(1-2):3-13. doi: 10.1016/j.jns.2005.03.031.
Reference Type
BACKGROUND
Barkhof F, Calabresi PA, Miller DH, Reingold SC. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol. 2009 May;5(5):256-66. doi: 10.1038/nrneurol.2009.41.
Reference Type
BACKGROUND
Altmann DR, Jasperse B, Barkhof F, Beckmann K, Filippi M, Kappos LD, Molyneux P, Polman CH, Pozzilli C, Thompson AJ, Wagner K, Yousry TA, Miller DH. Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology. 2009 Feb 17;72(7):595-601. doi: 10.1212/01.wnl.0000335765.55346.fc. Epub 2008 Nov 12.
Reference Type
BACKGROUND
Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, Brenner R, Chataway J, Hughes RA, Miller DH. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol. 2010 Jul;9(7):681-8. doi: 10.1016/S1474-4422(10)70131-9. Epub 2010 Jun 8.
Reference Type
BACKGROUND
Ebers GC, Heigenhauser L, Daumer M, Lederer C, Noseworthy JH. Disability as an outcome in MS clinical trials. Neurology. 2008 Aug 26;71(9):624-31. doi: 10.1212/01.wnl.0000313034.46883.16. Epub 2008 May 14.
Reference Type
BACKGROUND
Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):402-4. doi: 10.1136/jnnp.64.3.402.
Reference Type
BACKGROUND
Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology. 2003 Dec 23;61(12):1720-5. doi: 10.1212/01.wnl.0000098880.19793.b6.
Reference Type
BACKGROUND
Salzer J, Svenningsson A, Sundstrom P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler. 2010 Mar;16(3):287-92. doi: 10.1177/1352458509359725. Epub 2010 Jan 19.
Reference Type
BACKGROUND
Petzold A, Eikelenboom MJ, Keir G, Grant D, Lazeron RH, Polman CH, Uitdehaag BM, Thompson EJ, Giovannoni G. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. J Neurol Neurosurg Psychiatry. 2005 Feb;76(2):206-11. doi: 10.1136/jnnp.2004.043315.
Reference Type
BACKGROUND
Semra YK, Seidi OA, Sharief MK. Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability. J Neuroimmunol. 2002 Jan;122(1-2):132-9. doi: 10.1016/s0165-5728(01)00455-6.
Reference Type
BACKGROUND
Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, Giovannoni G. Quantification of neurodegeneration by measurement of brain-specific proteins. J Neuroimmunol. 2003 May;138(1-2):45-8. doi: 10.1016/s0165-5728(03)00092-4.
Reference Type
BACKGROUND
Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res. 2003 Oct 10;987(1):25-31. doi: 10.1016/s0006-8993(03)03219-0.
Reference Type
BACKGROUND
Kuhle J, Leppert D, Petzold A, Regeniter A, Schindler C, Mehling M, Anthony DC, Kappos L, Lindberg RL. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology. 2011 Apr 5;76(14):1206-13. doi: 10.1212/WNL.0b013e31821432ff. Epub 2011 Feb 23.
Reference Type
BACKGROUND
Petzold A, Rejdak K, Plant GT. Axonal degeneration and inflammation in acute optic neuritis. J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1178-80. doi: 10.1136/jnnp.2003.017236.
Reference Type
BACKGROUND
Gunnarsson M, Malmestrom C, Axelsson M, Sundstrom P, Dahle C, Vrethem M, Olsson T, Piehl F, Norgren N, Rosengren L, Svenningsson A, Lycke J. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol. 2011 Jan;69(1):83-9. doi: 10.1002/ana.22247. Epub 2010 Dec 8.
Reference Type
BACKGROUND
Gnanapavan S, Grant D, Morant S, Furby J, Hayton T, Teunissen CE, Leoni V, Marta M, Brenner R, Palace J, Miller DH, Kapoor R, Giovannoni G. Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression. PLoS One. 2013 Aug 1;8(8):e70019. doi: 10.1371/journal.pone.0070019. Print 2013.
Reference Type
BACKGROUND
Al-Izki S et al. Selective targeting of neuroprotection to MS lesions: sodium channel blockers in experimental autoimmune encephalomyelitis. In: Multiple Sclerosis Journal.; 2011:S53-S276
Reference Type
BACKGROUND
Koch MW, Polman SK. Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006453. doi: 10.1002/14651858.CD006453.pub2.
Reference Type
BACKGROUND
May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet. 2003;42(12):1023-42. doi: 10.2165/00003088-200342120-00002.
Reference Type
BACKGROUND
Lidster K et al. Neuroprotection in a novel optic neuritis model. In: Multiple Sclerosis Journal.; 2011:S227-S505 17
Reference Type
BACKGROUND
Solaro C, Restivo D, Mancardi GL, Tanganelli P. Oxcarbazepine for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study. Neurol Sci. 2007 Jun;28(3):156-8. doi: 10.1007/s10072-007-0811-3. Epub 2007 Jun 30.
Reference Type
BACKGROUND
Lu CH, Kalmar B, Malaspina A, Greensmith L, Petzold A. A method to solubilise protein aggregates for immunoassay quantification which overcomes the neurofilament "hook" effect. J Neurosci Methods. 2011 Feb 15;195(2):143-50. doi: 10.1016/j.jneumeth.2010.11.026. Epub 2010 Dec 4.
Reference Type
BACKGROUND
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444-52. doi: 10.1212/wnl.33.11.1444.
Reference Type
BACKGROUND
Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain. 2001 May;124(Pt 5):962-73. doi: 10.1093/brain/124.5.962.
Reference Type
BACKGROUND
Hobart J. The Multiple Sclerosis Impact Scale (MSIS-29). In: Quality of Life Measurement in Neurodegenerative and Related Conditions. Cambridge University Press; 2011:pp. 24-40
Reference Type
BACKGROUND
Sumowski JF, Wylie GR, Deluca J, Chiaravalloti N. Intellectual enrichment is linked to cerebral efficiency in multiple sclerosis: functional magnetic resonance imaging evidence for cognitive reserve. Brain. 2010 Feb;133(Pt 2):362-74. doi: 10.1093/brain/awp307. Epub 2009 Dec 14.
Reference Type
BACKGROUND
Henderson AP, Trip SA, Schlottmann PG, Altmann DR, Garway-Heath DF, Plant GT, Miller DH. A preliminary longitudinal study of the retinal nerve fiber layer in progressive multiple sclerosis. J Neurol. 2010 Jul;257(7):1083-91. doi: 10.1007/s00415-010-5467-x. Epub 2010 Feb 9.
Reference Type
BACKGROUND
Black JA, Liu S, Carrithers M, Carrithers LM, Waxman SG. Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann Neurol. 2007 Jul;62(1):21-33. doi: 10.1002/ana.21172.
Reference Type
BACKGROUND
Teunissen CE, Iacobaeus E, Khademi M, Brundin L, Norgren N, Koel-Simmelink MJ, Schepens M, Bouwman F, Twaalfhoven HA, Blom HJ, Jakobs C, Dijkstra CD. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology. 2009 Apr 14;72(15):1322-9. doi: 10.1212/WNL.0b013e3181a0fe3f.
Reference Type
BACKGROUND
Fisniku LK, Chard DT, Jackson JS, Anderson VM, Altmann DR, Miszkiel KA, Thompson AJ, Miller DH. Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol. 2008 Sep;64(3):247-54. doi: 10.1002/ana.21423.
Reference Type
BACKGROUND
Roosendaal SD, Bendfeldt K, Vrenken H, Polman CH, Borgwardt S, Radue EW, Kappos L, Pelletier D, Hauser SL, Matthews PM, Barkhof F, Geurts JJ. Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler. 2011 Sep;17(9):1098-106. doi: 10.1177/1352458511404916. Epub 2011 May 17.
Reference Type
BACKGROUND
Furby J, Hayton T, Altmann D, Brenner R, Chataway J, Smith KJ, Miller DH, Kapoor R. A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis. J Neurol. 2010 Sep;257(9):1508-16. doi: 10.1007/s00415-010-5563-y. Epub 2010 May 1.
Reference Type
BACKGROUND
Chard DT, Jackson JS, Miller DH, Wheeler-Kingshott CA. Reducing the impact of white matter lesions on automated measures of brain gray and white matter volumes. J Magn Reson Imaging. 2010 Jul;32(1):223-8. doi: 10.1002/jmri.22214.
Reference Type
BACKGROUND
Rocca MA, Horsfield MA, Sala S, Copetti M, Valsasina P, Mesaros S, Martinelli V, Caputo D, Stosic-Opincal T, Drulovic J, Comi G, Filippi M. A multicenter assessment of cervical cord atrophy among MS clinical phenotypes. Neurology. 2011 Jun 14;76(24):2096-102. doi: 10.1212/WNL.0b013e31821f46b8.
Reference Type
BACKGROUND
Furby J, Hayton T, Anderson V, Altmann D, Brenner R, Chataway J, Hughes R, Smith K, Miller D, Kapoor R. Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis. Mult Scler. 2008 Sep;14(8):1068-75. doi: 10.1177/1352458508093617. Epub 2008 Jul 16.
Reference Type
BACKGROUND
Kalkers NF, Barkhof F, Bergers E, van Schijndel R, Polman CH. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler. 2002 Dec;8(6):532-3. doi: 10.1191/1352458502ms849xx.
Reference Type
BACKGROUND
Horsfield MA, Sala S, Neema M, Absinta M, Bakshi A, Sormani MP, Rocca MA, Bakshi R, Filippi M. Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: application in multiple sclerosis. Neuroimage. 2010 Apr 1;50(2):446-55. doi: 10.1016/j.neuroimage.2009.12.121. Epub 2010 Jan 7.
Reference Type
BACKGROUND
Kearney H, Yiannakas MC, Abdel-Aziz K, Wheeler-Kingshott CA, Altmann DR, Ciccarelli O, Miller DH. Improved MRI quantification of spinal cord atrophy in multiple sclerosis. J Magn Reson Imaging. 2014 Mar;39(3):617-23. doi: 10.1002/jmri.24194. Epub 2013 Apr 30.
Reference Type
BACKGROUND
Inglese M, Madelin G, Oesingmann N, Babb JS, Wu W, Stoeckel B, Herbert J, Johnson G. Brain tissue sodium concentration in multiple sclerosis: a sodium imaging study at 3 tesla. Brain. 2010 Mar;133(Pt 3):847-57. doi: 10.1093/brain/awp334. Epub 2010 Jan 27.
Reference Type
BACKGROUND
Paling D et al. Total sodium concentration is increased in lesions and normal appearing white matter in Multiple Sclerosis. In: ISMRM.; 2012
Reference Type
BACKGROUND
Schneider T, Wheeler-Kingshott CA, Alexander DC. In-vivo estimates of axonal characteristics using optimized diffusion MRI protocols for single fibre orientation. Med Image Comput Comput Assist Interv. 2010;13(Pt 1):623-30. doi: 10.1007/978-3-642-15705-9_76.
Reference Type
BACKGROUND
Schneider T. Mapping the axon diameter index in the corpus callosum is clinically feasible. In: ISMRM.; 2012
Reference Type
BACKGROUND
Henderson AP, Trip SA, Schlottmann PG, Altmann DR, Garway-Heath DF, Plant GT, Miller DH. An investigation of the retinal nerve fibre layer in progressive multiple sclerosis using optical coherence tomography. Brain. 2008 Jan;131(Pt 1):277-87. doi: 10.1093/brain/awm285. Epub 2007 Dec 4.
Reference Type
BACKGROUND
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011 Dec;168(12):1266-77. doi: 10.1176/appi.ajp.2011.10111704.
Reference Type
BACKGROUND
Andersohn F, Schade R, Willich SN, Garbe E. Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. Neurology. 2010 Jul 27;75(4):335-40. doi: 10.1212/WNL.0b013e3181ea157e.
Reference Type
BACKGROUND
Al-Izki S, Pryce G, Hankey DJ, Lidster K, von Kutzleben SM, Browne L, Clutterbuck L, Posada C, Edith Chan AW, Amor S, Perkins V, Gerritsen WH, Ummenthum K, Peferoen-Baert R, van der Valk P, Montoya A, Joel SP, Garthwaite J, Giovannoni G, Selwood DL, Baker D. Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis. Brain. 2014 Jan;137(Pt 1):92-108. doi: 10.1093/brain/awt324. Epub 2013 Nov 27.
Reference Type
BACKGROUND
Davis A, Dobson R, Kaninia S, Espasandin M, Berg A, Giovannoni G, Schmierer K. Change practice now! Using atraumatic needles to prevent post lumbar puncture headache. Eur J Neurol. 2014 Feb;21(2):305-11. doi: 10.1111/ene.12307. Epub 2013 Dec 9.
Reference Type
BACKGROUND
Petzold A, Altintas A, Andreoni L, Bartos A, Berthele A, Blankenstein MA, Buee L, Castellazzi M, Cepok S, Comabella M, Constantinescu CS, Deisenhammer F, Deniz G, Erten G, Espino M, Fainardi E, Franciotta D, Freedman MS, Giedraitis V, Gilhus NE, Giovannoni G, Glabinski A, Grieb P, Hartung HP, Hemmer B, Herukka SK, Hintzen R, Ingelsson M, Jackson S, Jacobsen S, Jafari N, Jalosinski M, Jarius S, Kapaki E, Kieseier BC, Koel-Simmelink MJ, Kornhuber J, Kuhle J, Kurzepa J, Lalive PH, Lannfelt L, Lehmensiek V, Lewczuk P, Livrea P, Marnetto F, Martino D, Menge T, Norgren N, Papuc E, Paraskevas GP, Pirttila T, Rajda C, Rejdak K, Ricny J, Ripova D, Rosengren L, Ruggieri M, Schraen S, Shaw G, Sindic C, Siva A, Stigbrand T, Stonebridge I, Topcular B, Trojano M, Tumani H, Twaalfhoven HA, Vecsei L, Van Pesch V, Vanderstichele H, Vedeler C, Verbeek MM, Villar LM, Weissert R, Wildemann B, Yang C, Yao K, Teunissen CE. Neurofilament ELISA validation. J Immunol Methods. 2010 Jan 31;352(1-2):23-31. doi: 10.1016/j.jim.2009.09.014. Epub 2009 Oct 24.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-002419-87
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
14-LO-0185
Identifier Type: OTHER
Identifier Source: secondary_id
8722
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
The Possible Neuroprotective Effect of Ocrelizumab Via VEGF Protein Expression in Relapsing Multiple Sclerosis Patients
NCT04902690
UNKNOWN
Clinical Efficacy of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple Sclerosis
NCT02166021
COMPLETED
PHASE2
Patient Research Cohort: Rapidly Evolving Multiple Sclerosis
NCT01044576
COMPLETED
Phase II Clinical Trial of OCH-NCNP1
NCT04211740
COMPLETED
PHASE2
Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis
NCT00468611
TERMINATED
PHASE3
Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis
NCT01723631
TERMINATED
NA
Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis
NCT04261790
COMPLETED
PHASE4
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
NCT06564311
ACTIVE_NOT_RECRUITING
PHASE2
Mechanism of Action of Ocrelizumab in Multiple Sclerosis
NCT03344094
COMPLETED
A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis
NCT00035529
TERMINATED
PHASE2
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
NCT01081782
COMPLETED
PHASE2
Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset
NCT04466150
ACTIVE_NOT_RECRUITING
PHASE4
ATX-MS-1467 in Multiple Sclerosis
NCT01973491
COMPLETED
PHASE2
Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714
NCT03691077
UNKNOWN
PHASE3
Multiple Sclerosis-Simvastatin Trial 2
NCT03387670
COMPLETED
PHASE3
Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis
NCT00702468
COMPLETED
PHASE3
A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis
NCT07321093
RECRUITING
PHASE3
Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab
NCT03157830
COMPLETED
A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)
NCT00239655
TERMINATED
PHASE2
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574
NOT_YET_RECRUITING
PHASE2
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
NCT03290131
COMPLETED
PHASE3
A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis
NCT00257855
COMPLETED
PHASE2
Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
NCT00001248
RECRUITING
Effect of MD1003 in Spinal Progressive Multiple Sclerosis
NCT02220933
UNKNOWN
PHASE3